Viralytics receives $2.9M tax incentive

Company News

Viralytics Limited (ASX:VLA) has received $2.9 million from the Australian Taxation Office under the Research and Development Tax Incentive Programme.
 
The incentive relates to the financial year ending 30 June 2015.
 
Viralytics noted the funds will contribute towards advancing the clinical trial programme in the US and UK assessing CAVATAK.
 
CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against cancer cells. 
 
Viralytics recorded a net loss of $4.25 million at 30 June 2015.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?